A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The objective of this pivotal study is to evaluate the relative bioavailability of SYN010 HFA
Inhaler and Symbicort 160/4.5μg in healthy volunteers with charcoal block.
Phase:
Phase 1
Details
Lead Sponsor:
Intech Biopharm Ltd.
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Charcoal Formoterol Fumarate